NCT05952154

Brief Summary

The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of nonobstructive hypertrophic cardiomyopathy. This is a prospective, single-arm, single-center study.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jul 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2023

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

July 11, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 19, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

July 19, 2023

Status Verified

July 1, 2023

Enrollment Period

2 years

First QC Date

July 11, 2023

Last Update Submit

July 11, 2023

Conditions

Keywords

Nonobstructive Hypertrophic CardiomyopathySeptal MyectomyMitral RegurgitationTransapicalOff-pumpMinimally invasive

Outcome Measures

Primary Outcomes (2)

  • All-cause mortality

    Death from any cause during the observation period.

    3 months

  • Procedural success

    A reduction of ≥1 New York Heart Association (NYHA) class and a decrease of ≥ 20% of left atrial volume

    3 months

Secondary Outcomes (11)

  • Device success

    1 day

  • Septal thickness

    7 days and 3 months

  • Left ventricle mass

    7 days and 3 months

  • Left atrial volume

    7 days and 3 months

  • Major adverse cardiovascular and cerebral events

    3 months

  • +6 more secondary outcomes

Study Arms (1)

Nonbstructive Hypertrophic Cardiomyopathy

EXPERIMENTAL

Transapical beating-heart septal myectomy for the patient with nonobstructive hypertrophic cardiomyopathy and Heart Failure.

Procedure: Transapical beating-heart septal myectomy

Interventions

We have invented a beating-heart myectomy device.Through a minimally invasive intercostal incision, septal myectomy could be accomplished via a transapical access in the beating heart using the device. The whole process of resection is monitored, navigated, and evaluated by real-time transesophageal and transthoracic echocardiography. Left ventricular end-diastolic volume and the grade of mitral regurgitation are evaluated each time after resection. Multiple resections are performed to tailor the muscular resection for sufficient enlargement of left ventricular end-diastolic volume and improvement of mitral regurgitation, while preventing iatrogenic injuries.

Also known as: Minimally invasive transapical septal myectomy in the beating hearts
Nonbstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Age8 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients whose maximal ventricular septal wall thickness ≥ 15 mm.
  • Patients with heart function of New York Heart Association ≥ class II.
  • Patients with drug-refractory symptoms or intolerable to pharmaceutical therapies.
  • Patients who was informed the nature of the clinical trial, consented to participate in all of the activities of the clinical trial, and signed the informed consent form

You may not qualify if:

  • Patients who were pregnant.
  • Patients who had concomitant diseases such as intrinsic valvular disease or coronary artery disease that needed open-heart surgery.
  • Patients who had severe heart failure with left ventricle ejection fraction \< 40%.
  • Patients whose estimated life expectancy \< 12 m.
  • Patient who were non-compliant.
  • Patients under circumstances which were considered not suitable or prohibitive for participating the clinical trial at the discretion of the attending medical team and the researchers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

Related Publications (1)

  • Fang J, Wang R, Liu H, Su Y, Chen J, Han X, Wei Y, Chen Y, Cheng L, Wei X. Transapical septal myectomy in the beating heart via a minimally invasive approach: a feasibility study in swine. Interact Cardiovasc Thorac Surg. 2020 Feb 1;30(2):303-311. doi: 10.1093/icvts/ivz249.

    PMID: 31642911BACKGROUND

MeSH Terms

Conditions

Mitral Valve Insufficiency

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Experimental Group: Beating-heart myectomy device
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor and Director

Study Record Dates

First Submitted

July 11, 2023

First Posted

July 19, 2023

Study Start

July 1, 2023

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

July 19, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will share

All of the conclusive participant data, after removing the individual information of privacy, will be uploaded as supporting information when publishing the current study.

Shared Documents
STUDY PROTOCOL, SAP, CSR
Time Frame
After the current study is published.
Access Criteria
All readers who were interested in the current study.

Locations